ArticleThe Journal of clinical psychiatry2016
Nonmedical Prescription Opioid Use and DSM-5 Nonmedical Prescription Opioid Use Disorder in the United States.
Article in The Journal of clinical psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
129 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Health harms of non-medical prescription opioid use: A systematic review.Drug and alcohol review · 2022Pooled it
- General practitioners' attitudes towards opioids for non-cancer pain: a qualitative systematic review.BMJ open · 2022Pooled it
- Treatment-seeking behaviour among people with opioid use disorder in the high-income countries: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Global patterns of opioid use and dependence: harms to populations, interventions, and future action.Lancet (London, England) · 2019Pooled it
- An Evaluation of Opioid Use in Black Communities: A Rapid Review of the Literature.Harvard review of psychiatryPooled it
- Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder.Harm reduction journal · 2023Trial
- Opioid Misuse as a Predictor of Alcohol Treatment Outcomes in the COMBINE Study: Mediation by Medication Adherence.Alcoholism, clinical and experimental research · 2018Trial
- A systematic review of the prevalence and correlates of mental and substance use disorders in first nations peoples in Australia, New Zealand, Canada and the United States of America.Social psychiatry and psychiatric epidemiology · 2026Review
- Reducing opioid prescriptions does not increase rate of refills or new opioid requests: evidence from a randomized trial.Health affairs scholar · 2026Article
- Integrating an exercise program into opioid agonist therapy: a pilot study on feasibility, fitness improvements, and participation challenges.Addiction science & clinical practice · 2025Article
- Communication-efficient federated learning of temporal effects on opioid use disorder with data from distributed research networks.Journal of the American Medical Informatics Association : JAMIA · 2025Article
- The impact of buprenorphine prescriber data on geospatial access to treatment in HEALing Communities Study communities, 2022.Journal of substance use and addiction treatment · 2025Article
- Does opioid therapy enhance quality of life in patients suffering from chronic non-malignant pain? A systematic review and meta-analysis.British journal of pain · 2024Article
- Developing practical strategies to reduce addiction-related stigma and discrimination in public addiction treatment centers: a mixed-methods study protocol.Addiction science & clinical practice · 2024Article
- Remote cognitive behavioral therapy utilizing an in-home virtual reality toolkit (Vx Therapy) reduces pain, anxiety, and depression in patients with chronic cervical and lumbar spondylytic pain: A potential alternative to opioids in multimodal pain management.North American Spine Society journal · 2023Article
- Opioid use disorder in two samples of the Lebanese population: scale validation and correlation with sleep and mood disorders.BMC psychiatry · 2023Article
- Characteristics Associated with Multimorbidity among Older United States Adult Opioid Users with Pain.Journal of clinical medicine · 2023Article
- A Diagram of the Social-Ecological Conditions of Opioid Misuse and Overdose.International journal of environmental research and public health · 2023Review
- Alcohol Use Among Treatment-Seeking Individuals With Opioid Use Disorder.Journal of studies on alcohol and drugs · 2023Article
- Longitudinal associations between age 20 problematic substance use and opioid use disorder incidence at age 30 - findings from an urban cohort.Journal of psychiatric research · 2023Article
69 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveThe authors present 12-month and lifetime prevalence, correlates, psychiatric comorbidity, and treatment of nonmedical prescription opioid use (NMPOU) and DSM-5 NMPOU disorder (NMPOUD).
methodsData were derived from the 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III) (N = 36,309).
resultsPrevalences of 12-month and lifetime NMPOU were 4.1% and 11.3%, exceeding rates in the 2001-2002 NESARC (1.8%, 4.7%). Twelve-month and lifetime rates of DSM-5 NMPOUD were 0.9% and 2.1%. NESARC-III DSM-IV NMPOUD rates (0.8%, 2.9%) were greater than those observed in the 2001-2002 NESARC (0.4% and 1.4%). Rates of NMPOU were greater among men, but no sex differential was observed for NMPOUD. Prevalences of NMPOU and NMPOUD were generally greater among 18- to 64-year-old individuals, whites, and Native Americans, and individuals with lower socioeconomic status. Associations were observed between 12-month and lifetime NMPOU and NMPOUD and other drug use disorders, posttraumatic stress disorder, and borderline, schizotypal, and antisocial personality disorders; persistent depression and major depressive disorder (for NMPOU); and bipolar I disorder (for NMPOUD). Only 5.5% and 17.7% of individuals with 12-month NMPOU and NMPOUD were ever treated.
conclusionsNMPOU and NMPOUD have considerably increased over the past decade, are associated with a broad array of risk factors and comorbidities, and largely go untreated in the United States. More information on the determinants, characteristics, and outcomes of NMPOU and NMPOUD is needed to support evidence-based interventions and prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.